Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin Basic Protein-Specific Autoreactive CD4+ and CD8+ T Lymphocytes (MBP-specific autoreactive T cells)
- Target
- MBP-specific autoreactive T cells
- Molecular classification
- T lymphocytes, CD4+ T cells, CD8+ T cells, Immune cells
01
Overview
Myelin basic protein (MBP)-specific autoreactive T lymphocytes are immune cells that recognize and respond to MBP, a key structural component of the myelin sheath in the central nervous system. Both CD4+ (helper) and CD8+ (cytotoxic) T cell subsets can become autoreactive against MBP, contributing to autoimmune demyelinating diseases such as multiple sclerosis (MS). CD4+ T cells orchestrate inflammation via cytokine secretion, while CD8+ T cells directly lyse oligodendrocytes expressing target antigens. Autoreactivity arises due to failures in central tolerance and potential cross-reactivity with microbial antigens. Therapeutic strategies aim to deplete or functionally modulate these autoreactive T cells.
- Other names
- MBP-specific CD4+ T cellsMBP-specific CD8+ T cellsMyelin-reactive CD4+ T lymphocytesMyelin-reactive CD8+ T lymphocytesAutoreactive T cells to Myelin Basic Protein
02
Mechanism of action
Depletion or functional modulation of autoreactive T cells
03
Biological functions
Immune responseT cell activationCytokine productionCytotoxicityAntigen recognitionAutoimmunity
04
Disease associations
Multiple SclerosisExperimental Autoimmune Encephalomyelitis (EAE)Autoimmune demyelinating diseases
05
Safety considerations
Potential for broad immunosuppressionRisk of exacerbating autoimmune diseaseOff-target effects of T cell modulationCytokine release syndrome
06
Interacting drugs
T cell vaccination (attenuated autologous clones)
07
Biomarkers
Frequency of MBP-specific T cells in blood/CNSCytokine profile (IFN-gamma, TNF-alpha, IL-10)HLA restriction (HLA-DR, HLA-A2, HLA-A24)Expression of CD3, CD4, CD8 markers
Beyond the preview
Go deeper on Myelin Basic Protein-Specific Autoreactive CD4+ and CD8+ T Lymphocytes (MBP-specific autoreactive T cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myelin Basic Protein-Specific Autoreactive CD4+ and CD8+ T Lymphocytes (MBP-specific autoreactive T cells).